BTSA1.2 is a rationalized BTSA1 analog with improved binding to BAX, cellular cytotoxicity, and better toleratence in vivo. Combination of BTSA1.2 with Navitoclax demonstrates synergistic efficacy in apoptosis-resistant cancer cells, xenografts, and patient-derived tumors while sparing healthy tissues.

Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

[1] Promising approach against treatment-resistant cancer. Retrieved Mar 8th, 2022 from https://medicalxpress.com/news/2022-03-approach-treatment-resistant-cancer.html [2] Andrea Lopez et al, Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer, Nature Communications (2022). DOI: 10.1038/s41467-022-28741-7